Could a single injection replace surgery for hammertoes?
NCT ID NCT07759362
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This Phase 3 trial tests an injectable treatment called KN3835 against a placebo in about 554 people with flexible or semi-flexible hammertoes. The goal is to see if KN3835 can reduce the toe's bending and improve foot function and pain. Participants receive either the treatment or a placebo injection, and their progress is measured over about two months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KN3835, an injectable biological treatment
- What this could lead to
- If successful, KN3835 could offer a non-surgical way to correct flexible hammertoes and reduce foot pain and disability.
- What could go wrong
- This is an early-stage test in a large group, and results may not match real-world outcomes. Possible side effects include injection-site reactions or the treatment not working for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FLEXIBLE HAMMERTOE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.